ReP USP - Resultado da busca

Artigo de periodico
Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays (2013)
Rezende, Vinicius Marcondes; Rivellis, Ariane; Novaes, Mafalda Megumi Yoshinaga; Chamone, Dalton de Alencar Fisher; Bendit, Israel
Source: Drug Design, Development and Therapy. Unidade: FM
Subjects: LEUCEMIA MILÓIDE (TERAPIA), CROMATOGRAFIA, BIOEQUIVALÊNCIA, REAÇÃO EM CADEIA POR POLIMERASE, ANTINEOPLÁSICOS (APLICAÇÕES TERAPÊUTICAS), ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REZENDE, Vinicius Marcondes et al. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Design, Development and Therapy, v. 7, p. 699\2013710, 2013Tradução . . Disponível em: https://doi.org/10.2147/DDDT.S42902. Acesso em: 06 nov. 2024.
APA
Rezende, V. M., Rivellis, A., Novaes, M. M. Y., Chamone, D. de A. F., & Bendit, I. (2013). Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. Drug Design, Development and Therapy, 7, 699\2013710. doi:10.2147/DDDT.S42902
NLM
Rezende VM, Rivellis A, Novaes MMY, Chamone D de AF, Bendit I. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays [Internet]. Drug Design, Development and Therapy. 2013 ; 7 699\2013710.[citado 2024 nov. 06 ] Available from: https://doi.org/10.2147/DDDT.S42902
Vancouver
Rezende VM, Rivellis A, Novaes MMY, Chamone D de AF, Bendit I. Quantification of imatinib in human serum: Validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays [Internet]. Drug Design, Development and Therapy. 2013 ; 7 699\2013710.[citado 2024 nov. 06 ] Available from: https://doi.org/10.2147/DDDT.S42902
Artigo de periodico
Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance (2013)
Rezende, Vinícius Marcondes; Rivellis, Ariane Julio; Gomes, Melissa Medrano; Dörr, Felipe Augusto; Novaes, Mafalda Megumi Yoshinaga; Nardinelli, Luciana; Costa, Ariel Lais de Lima; Chamone, Dalton de Alencar Fisher; Bendit, Israel
Source: Revista brasileira de hematologia e hemoterapia. Unidades: FM, FCF
Subjects: LEUCEMIA MIELOIDE, DOENÇA CRÔNICA, MONITORIZAÇÃO FISIOLÓGICA, ANTINEOPLÁSICOS (ADMINISTRAÇÃO E DOSAGEM), CROMATOGRAFIA LÍQUIDA, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA, ESPECTROMETRIA DE MASSAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
REZENDE, Vinícius Marcondes et al. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Revista brasileira de hematologia e hemoterapia, v. 35, n. 2, p. 103-108, 2013Tradução . . Disponível em: https://doi.org/10.5581/1516-8484.20130030. Acesso em: 06 nov. 2024.
APA
Rezende, V. M., Rivellis, A. J., Gomes, M. M., Dörr, F. A., Novaes, M. M. Y., Nardinelli, L., et al. (2013). Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. Revista brasileira de hematologia e hemoterapia, 35( 2), 103-108. doi:10.5581/1516-8484.20130030
NLM
Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MMY, Nardinelli L, Costa AL de L, Chamone D de AF, Bendit I. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance [Internet]. Revista brasileira de hematologia e hemoterapia. 2013 ; 35( 2): 103-108.[citado 2024 nov. 06 ] Available from: https://doi.org/10.5581/1516-8484.20130030
Vancouver
Rezende VM, Rivellis AJ, Gomes MM, Dörr FA, Novaes MMY, Nardinelli L, Costa AL de L, Chamone D de AF, Bendit I. Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance [Internet]. Revista brasileira de hematologia e hemoterapia. 2013 ; 35( 2): 103-108.[citado 2024 nov. 06 ] Available from: https://doi.org/10.5581/1516-8484.20130030
Artigo de periodico
Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia (2012)
Nardinelli, Luciana; Sanabani, Sabri Saeed; Didone, Alline; Ferreira, Patricia de Barros; Serpa, Mariana; Novaes, Mafalda Megumi Yoshinaga; Marchiani, Mariana; Ruiz, Antonio Lancha; Lima, Ismael Severino; Chamone, Dalton de Alencar Fischer; Bendit, Israel
Source: Acta Haematologica. Unidade: FM
Subjects: EXPRESSÃO GÊNICA, DOENÇA CRÔNICA, BIOLOGIA MOLECULAR, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NARDINELLI, Luciana et al. Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia. Acta Haematologica, v. 127, n. 4, p. 228-234, 2012Tradução . . Disponível em: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000336610. Acesso em: 06 nov. 2024.
APA
Nardinelli, L., Sanabani, S. S., Didone, A., Ferreira, P. de B., Serpa, M., Novaes, M. M. Y., et al. (2012). Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia. Acta Haematologica, 127( 4), 228-234. doi:10.1159/000336610
NLM
Nardinelli L, Sanabani SS, Didone A, Ferreira P de B, Serpa M, Novaes MMY, Marchiani M, Ruiz AL, Lima IS, Chamone D de AF, Bendit I. Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia [Internet]. Acta Haematologica. 2012 ; 127( 4): 228-234.[citado 2024 nov. 06 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000336610
Vancouver
Nardinelli L, Sanabani SS, Didone A, Ferreira P de B, Serpa M, Novaes MMY, Marchiani M, Ruiz AL, Lima IS, Chamone D de AF, Bendit I. Pretherapeutic Expression of the hOCT1 Gene Predicts a Complete Molecular Response to Imatinib Mesylate in Chronic-Phase Chronic Myeloid Leukemia [Internet]. Acta Haematologica. 2012 ; 127( 4): 228-234.[citado 2024 nov. 06 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000336610
Artigo de periodico
Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute (2012)
Bendit, Israel; Sanabani, Sabri Saeed; Conchon, Monika; Serpa, Mariana; Novaes, Mafalda Megumi Yoshinaga; Nardinelli, Luciana; Pereira, Thales Dalessandro Meneguin; Tucunduva, Luciana; Ferreira, Patricia de Barros; Dorlhiac-Llacer, Pedro Enrique; Chamone, Dalton de Alencar Fischer
Source: Acta Haematologica. Unidade: FM
Subjects: CITOGENÉTICA MOLECULAR (AVALIAÇÃO), DOENÇA CRÔNICA, INTERFERONS, FASES, LEUCEMIA MIELOIDE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BENDIT, Israel et al. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. Acta Haematologica, v. 128, n. 4, p. 223-232, 2012Tradução . . Disponível em: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696. Acesso em: 06 nov. 2024.
APA
Bendit, I., Sanabani, S. S., Conchon, M., Serpa, M., Novaes, M. M. Y., Nardinelli, L., et al. (2012). Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute. Acta Haematologica, 128( 4), 223-232. doi:10.1159/000339696
NLM
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MMY, Nardinelli L, Pereira TDM, Tucunduva L, Ferreira P de B, Dorlhiac-Llacer PE, Chamone D de AF. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute [Internet]. Acta Haematologica. 2012 ; 128( 4): 223-232.[citado 2024 nov. 06 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696
Vancouver
Bendit I, Sanabani SS, Conchon M, Serpa M, Novaes MMY, Nardinelli L, Pereira TDM, Tucunduva L, Ferreira P de B, Dorlhiac-Llacer PE, Chamone D de AF. Evaluation of Long-Term Outcomes, Cytogenetic and Molecular Responses with Imatinib Mesylate in Early and Late Chronic-Phase Chronic Myeloid Leukemia: A Report from a Single Institute [Internet]. Acta Haematologica. 2012 ; 128( 4): 223-232.[citado 2024 nov. 06 ] Available from: http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000339696

USP Schools

ReP

Filtros

Authors

Subjects

Indexado em